

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1 - 54. (Cancelled)

55. (Currently Amended) A method of treating a cancer ~~cancers~~ having a zyxin gene expression/abnormality selected from the group consisting of hepatocarcinomas, mesenchymal tumors, neuroectodermal cancer, Ewing's sarcoma, melanoma, and malignant hemopathies associated with chromosomal anomalies of region of 7q34/q35 of zyxin gene, comprising administering a therapeutically effective amount of a composition comprising an active agent which stabilizes an actin network of a cellular cytoskeleton and wherein said active agent is ~~selected from the group consisting of:~~

~~a zyxin protein or a polypeptide fragment thereof, a nucleic acid molecule comprising cDNA of a zyxin gene, a fragment thereof or a complementary sequence, or an antisense nucleic acid thereof, a cell or set of cells overexpressing the zyxin gene or a functional fragment thereof,~~

~~an inhibitor of cofilin, and~~

~~a cyclic peptide dolastatin 11,~~

to a patient in need thereof.

56-58. (Cancelled)

59. (Currently Amended) The method according to claim ~~58~~ 55, wherein said ~~cancers are~~ cancer is Ewing's sarcoma.

60-61. (Cancelled)

62. (Currently Amended) ~~The A~~ method of treating a cancer ~~cancers~~ having a zyxin gene expression/abnormality selected from the group consisting of hepatocarcinomas, mesenchymal tumors, neuroectodermal cancer, Ewing's sarcoma, melanoma, and malignant hemopathies associated with chromosomal anomalies of region of 7q34/q35 of zyxin gene, comprising:

- a) identifying a subject having said cancer ~~tumor~~ underexpressing a zyxin gene;
- b) administering a therapeutically effective amount of a pharmaceutical composition to the subject ~~identified with the tumor~~, the composition comprising:
 - (i) ~~a zyxin protein or a polypeptide fragment thereof, a nucleic acid molecule comprising cDNA of a zyxin gene, a fragment thereof or a complementary sequence, or an antisense nucleic acid thereof, a cell or set of cells overexpressing the zyxin gene or a functional fragment thereof~~ dolastatin 11 and
 - (ii) a pharmaceutically acceptable carrier.

63. (Currently amended) The method according to claim 62, wherein said ~~cancers are~~ cancer is selected from the group consisting of Ewing's sarcoma and melanoma.

64. (Currently Amended) The method according to claim 63, wherein said ~~cancers are~~ cancer is Ewing's sarcoma.

65-69. (Cancelled)